metotreksat ebewe 100 mg/ml koncentrat za raztopino za infundiranje
ebewe pharma - metotreksat - koncentrat za raztopino za infundiranje - metotreksat 100 mg / 1 ml - metotreksat
metotreksat ebewe 100 mg/ml koncentrat za raztopino za infundiranje
ebewe pharma - metotreksat - koncentrat za raztopino za infundiranje - metotreksat 100 mg / 1 ml - metotreksat
trobalt
glaxo group limited - retigabin - epilepsija - antiepileptics, - zdravilo trobalt je indicirano kot dodatno zdravljenje epileptičnih napadov z odpornimi proti drogam s sekundarno generalizacijo ali brez nje pri bolnikih, starih 18 let ali več, pri katerih so se druge primerne kombinacije zdravil izkazale za neustrezne ali niso bile tolerirane.
exalief
bial - portela ca, s.a. - eslikarbazepin acetat - epilepsija - antiepileptics, - zdravilo exalief je indicirano kot dodatno zdravljenje pri odraslih z epileptičnim napadom s sekundarno generalizacijo ali brez nje.
briviact (in italy: nubriveo)
ucb pharma sa - brivaracetam - epilepsija - antiepileptics, - briviact je indiciran kot dodatna terapija pri zdravljenju napadov s parcialnim nastopom s sekundarno generalizacijo ali brez nje pri odraslih in mladostnikih, starih od 16 let, z epilepsijo.
fycompa
eisai gmbh - perampanel - epilepsije, delno - antiepileptics, druge antiepileptics - zdravilo fycompa je indicirano za dodatno zdravljenje epileptičnih napadov z ali brez sekundarnih generaliziranih napadov pri odraslih in mladostnikih, starih od 12 let, z epilepsijo. fycompa je primerna za adjunctive zdravljenju primarne splošni tonik-clonic zasegov v izobraževanju odraslih in mladostnikov bolnikih od 12. leta starosti z idiopatsko splošnih epilepsijo.
abecma
bristol-myers squibb pharma eeig - idecabtagene vicleucel - multiple myeloma; neoplasms; cancer; neoplasms, plasma cell; hemostatic disorders; vascular diseases; cardiovascular diseases; paraproteinemias; blood protein disorders; hematologic diseases; hemic and lymphatic diseases; hemorrhagic disorders; infectious mononucleosis; lymphoproliferative disorders; immunoproliferative disorders; immune system diseases - antineoplastična sredstva - abecma is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti cd38 antibody and have demonstrated disease progression on the last therapy.
breyanzi
bristol-myers squibb pharma eeig - cd19-directed genetically modified autologous cell-based product consisting of purified cd8+ t-cells (cd8+ cells), cd19-directed genetically modified autologous cell-based product consisting of purified cd4+ t cells (cd4+ cells) - lymphoma, large b-cell, diffuse; lymphoma, follicular; mediastinal neoplasms - antineoplastična sredstva - breyanzi is indicated for the treatment of adult patients with diffuse large b-cell lymphoma (dlbcl), high grade b-cell lymphoma (hgbcl), primary mediastinal large b-cell lymphoma (pmbcl) and follicular lymphoma grade 3b (fl3b), who relapsed within 12 months from completion of, or are refractory to, first-line chemoimmunotherapy.
talvey
janssen-cilag international n.v. - talquetamab - multiple myeloma - antineoplastična sredstva - talvey is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least 3 prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti cd38 antibody and have demonstrated disease progression on the last therapy.
tepkinly
abbvie deutschland gmbh & co. kg - epcoritamab - lymphoma, large b-cell, diffuse - antineoplastična sredstva - tepkinly as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large b-cell lymphoma (dlbcl) after two or more lines of systemic therapy.